Literature DB >> 23400502

Successful treatment of CANOMAD with IVIg and rituximab.

Wolfgang N Löscher, Alexander Woertz, Monika Wallnöfer, Julia V Wanschitz, Gerhard Luef.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23400502     DOI： 10.1007/s00415-013-6867-5

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies.

Authors:  K Siddiqui; E Cahalane; M Keogan; O Hardiman
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

2.  Long-term effect of rituximab in anti-mag polyneuropathy.

Authors:  L Benedetti; C Briani; D Franciotta; M Carpo; L Padua; G Zara; R Zambello; M P Sormani; G L Mancardi; E Nobile-Orazio; A Schenone
Journal:  Neurology       Date:  2008-11-18       Impact factor: 9.910

3.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.

Authors: 
Journal:  J Peripher Nerv Syst       Date:  2010-09       Impact factor: 3.494

4.  Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Authors:  Emilien Delmont; P Y Jeandel; A M Hubert; L Marcq; J Boucraut; C Desnuelle
Journal:  J Neurol       Date:  2009-12-04       Impact factor: 4.849

5.  Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Authors:  Emilien Delmont; P Y Jeandel; C Benaïm; E Rosenthal; J G Fuzibet; C Desnuelle
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

6.  Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody.

Authors:  K Susuki; N Yuki; K Hirata
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

7.  Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy.

Authors:  M Eurelings; C W Ang; N C Notermans; P A Van Doorn; B C Jacobs; L H Van den Berg
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

8.  The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies.

Authors:  H J Willison; C P O'Leary; J Veitch; L D Blumhardt; M Busby; M Donaghy; P Fuhr; H Ford; A Hahn; S Renaud; H A Katifi; S Ponsford; M Reuber; A Steck; I Sutton; W Schady; P K Thomas; A J Thompson; J M Vallat; J Winer
Journal:  Brain       Date:  2001-10       Impact factor: 13.501

9.  Rituximab for polyneuropathy with IgM monoclonal gammopathy.

Authors:  J M F Niermeijer; M Eurelings; H L Lokhorst; W-L van der Pol; H Franssen; J H J Wokke; N C Notermans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09       Impact factor: 10.154

10.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

Authors:  Marinos C Dalakas; Goran Rakocevic; Mohammad Salajegheh; James M Dambrosia; Angelika F Hahn; Raghavan Raju; Beverly McElroy
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422
  10 in total
  7 in total

Review 1.  Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.

Authors:  D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette
Journal:  J Neurol       Date:  2020-04-28       Impact factor: 4.849

Review 2.  [Polyneuropathy in older individuals].

Authors:  W N Löscher; B Iglseder
Journal:  Internist (Berl)       Date:  2020-03       Impact factor: 0.743

Review 3.  Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.

Authors:  Abraham C J Stork; W-Ludo van der Pol; Hessel Franssen; Bart C Jacobs; Nicolette C Notermans
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

4.  CANOMAD unmasked by COVID-19 in a man with Waldenström's macroglobulinaemia.

Authors:  Hamish D Morrison; Jonathan Cleaver; Natasha Lander; Philippa Lowden; Kate Hale; Kanchan Sharma; James Stevens
Journal:  EJHaem       Date:  2021-08-12

5.  CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg).

Authors:  Martin Krenn; Geoff Keir; Udo Carl Wieshmann
Journal:  BMJ Case Rep       Date:  2014-04-10

6.  CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA).

Authors:  Rocio Garcia-Santibanez; Craig M Zaidman; R Brian Sommerville; Glenn Lopate; Conrad C Weihl; Alan Pestronk; Robert C Bucelli
Journal:  J Neurol       Date:  2018-04-09       Impact factor: 4.849

7.  Facial Involuntary Movements and Respiratory Failure in CANOMAD, Responsive to IVIG Therapy.

Authors:  Kate Johnson; Ashish Malkan; Mohamed Shaffi
Journal:  Case Rep Med       Date:  2015-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.